Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexucabtagene Autoleucel in Rare B-cell Malignancies (ZUMA-25)
NCT05537766Phase 2Terminated
- Sponsor
- Kite Pharma
- Start
- Nov 2022
- Primary completion
- Jan 2025
- Countries
- 8
01
Overview
Phase 2, open-label trial of brexucabtagene autoleucel in Waldenstrom macroglobulinemia (WM), Richter's syndrome (RS), Burkitt lymphoma (BL) and 1 more, sponsored by Kite Pharma. Primary endpoints: Combined Rate of Complete Response and Very Good Partial Response (Substudy A) at 2 years, Objective Response Rate (Substudy B) at 2 years and 2 more. Started Nov 2022; status: terminated.
02
Drugs
brexucabtagene autoleucel
03
Conditions
Waldenstrom macroglobulinemia (WM)Richter's syndrome (RS)Burkitt lymphoma (BL)hairy cell leukemia (HCL)
Beyond the preview
Go deeper on NCT05537766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05537766.